Why Investors Should Buy Canopy Growth Stock

Canopy Growth (NYSE:CGC) stock exploded higher at the beginning of 2019 on the back of favorable trends and fundamentals underlying both the company and marijuana stocks in general. At the start of 2019, CGC stock wastrading hands around $25. By the end of April, CGC stock had more than doubled, having risen above $50.

Source: Shutterstock

But Canopy stock has not been immune to recent stock-market weakness. Specifically, as global financial markets sold off in May due to escalating trade conflicts, shares of Canopy Growth fell, too. At the end of May, Canopy Growth stock was slightly above $40, and it closed yesterday at $41.40.

• 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3%

Investors worry that trade conflicts could stall the global economy and stunt the expansion of the booming cannabis market. There are also concerns related to continued supply shortages in the Canadian cannabis market, as well as mixed comments from the FDA regarding potential CBD legalization in the United States.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

These concerns are overstated. Trade conflicts and tariffs are a near term phenomena. Supply shortages and the FDA’s hesitancy about legalizing CBD will also dissipate over the longer term.

In the long run, all these headwinds will reverse. Thus, when it comes to the cannabis market, investors would be wise to focus on the forest instead of the trees. When they do that, they will see that the non-cyclical growth outlook of the cannabis market remains as favorable as ever.

Further, CGC stock should find technical support at $40, and positive fundamental developments over the next few months should send CGC stock price back to and even above $50. As a result, this dip looks like a good time to buy CGC stock.

Three Concerns Are Killing Canopy Stock

At present, there are three factors weighing on Canopy Growth  stock and other cannabis companies.

First, escalating trade tensions and the threat of bigger and more widespread tariffs are hurting marijuana stocks. Cannabis companies look poised to produce and transport cannabis all over the world, putting them at the epicenter of the present trade conflicts. If these conflicts persist for much longer, then as the cannabis market matures and expands, it will inevitably run into tariff headwinds.

Second, Canadian cannabis companies continue to struggle to keep up with demand. Supply shortages have been the theme of the legal Canadian cannabis market since its inception. As long as these supply shortages persist, cannabis companies will fail to fully capture the robust demand for marijuana in Canada.

Third, legalization of CBD in the U.S. took a step back as the FDA issued mixed comments regarding the healthiness of CBD. Broadly, the FDA said it doesn’t know much about CBD, implying that the substance will only be legalized after the agency studies the drug further, and that could take some time.

These Concerns Are Overstated

These concerns are overstated, mostly because they are all near-term in nature, while the long-term growth outlook underlying CGC stock is positive.

This isn’t the first trade war the U.S. has been in, and it won’t be the last. Looking at those other trade conflicts, we can see that they don’t stick around forever. They usually get resolved within a few years or less.

Further, supply shortages in Canada likewise won’t last forever, as Canopy is rapidly expanding its production to meet the country’s robust demand. And, lastly, 11 states in the U.S. have already legalized cannabis, and it really is only a matter of time before CBD is legalized throughout the U.S.

Overall, then, the present challenges facing the cannabis market and CGC stock are overstated, because they do not impact their long-term growth outlook.

Canopy Growth Stock Looks Good at This Point

The cannabis market is well-positioned to become a $200 billion-plus market globally one day, and Canopy – given its current leadership position and resource advantages – looks poised to become the leader of that market. Even if it attains just a 10% share of the cannabis market, its sales will eventually reach $20 billion, which makes today’s $14.3 billion market cap of CGC stock seem like a steal.